Lipella Pharmaceuticals Inc (LIPO)
Lipella Pharmaceuticals Inc. is a clinical-stage biotechnology company listed on OTC Markets under the symbol LIPO. The company focuses on reformulating active ingredients from existing generic drugs and adapting those formulations for specific medical uses. Its development pipeline includes LP-10, a tacrolimus formulation being studied for radiation-induced hemorrhagic cystitis; LP-310, also based on tacrolimus and aimed at oral lichen planus; LP-410, an oral liposomal tacrolimus formulation for oral graft-versus-host disease; and LP-50, an intravesical immunoglobulin formulation being developed for non-muscle invasive bladder cancer. Lipella Pharmaceuticals was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania. On March 30, 2026, the company filed a voluntary Chapter 11 reorganization petition in the U.S. Bankruptcy Court for the Western District of Pennsylvania.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-LIPO
|
$0.065
|
98.8% Upside
|
Bargain
|
—
|
—
|
—
|
Weak
|
—
|
—
|
—
|
0.0%
|
September 2, 2026
|
0.0x
|
0.1x
|
0.4x
|
151.101 K
|
-1.441 M
|
63.6%
|
93.7%
|
-33.1
|
—
|
89.6%
|
